1. Spiegel H, Spiegel D. Trance and treatment: clinical uses of hypnosis. 2nd ed. Washington, DC: American Psychiatric Pub; 2004.
2. Tellegen A, Atkinson G. Openness to absorbing and self-altering experiences (“absorption”), a trait related to hypnotic susceptibility. J Abnorm Psychol. 1974 Jun;83(3):268–277.
3. Spiegel D. Tranceformations: hypnosis in brain and body. Depress Anxiety. 2013 Apr;30(4):342–352.
4. Spiegel H, Greenleaf M, Spiegel D. Hypnosis. In: Sadock VA, editor. Kaplan Sadocks Compr Textb Psychiatry. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 2128–2145.
5. Hoeft F, Gabrieli JDE, Whitfield-Gabrieli S, et al. Functional brain basis of hypnotizability. Arch Gen Psychiatry. 2012 Oct;69(10):1064–1072.
6. Craig ADB. Significance of the insula for the evolution of human awareness of feelings from the body. Ann N Y Acad Sci. 2011 Apr;1225:72–82.
7. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci. 1996 Oct 29;351(1346):1413–1420.
8. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci Off J Soc Neurosci. 2007 Feb 28;27(9):2349–2356.
9. Aybek S, Nicholson TR, Zelaya F, et al. Neural correlates of recall of life events in conversion disorder. JAMA Psychiatry. 2014 Jan;71(1):52–60.
10. Baslet G. Psychogenic non-epileptic seizures: a model of their pathogenic mechanism. Seizure. 2011 Jan;20(1):1–13.
11. Voon V, Gallea C, Hattori N, Bruno M, Ekanayake V, Hallett M. The involuntary nature of conversion disorder. Neurology. 2010 Jan 19;74(3):223–228.
12. Voon V, Brezing C, Gallea C, et al. Emotional stimuli and motor conversion disorder. Brain J Neurol. 2010 May;133(Pt 5):1526–1536.
13. Moene FC, Kuyk J. Hypnosis in the treatment of psychogenic nonepileptic seizures. In: Schachter SC, LaFrance WC, Gates JR, editors. Gates Rowans Nonepileptic Seizures. 3rd ed. Cambridge ; New York: Cambridge University Press; 2010. p. 297–306.
14 Barry JJ. Hypnosis and psychogenic movement disorders. Psychogenic Mov Disord Neurol Neuropsychiatry. Lippincott Williams & Wilkins; 2006. p. 241–248.
15. Barry JJ. Nonepileptic seizures: an overview. CNS Spectr. 2001 Dec;6(12):956–962.
16. Schoenberger NE. Research on hypnosis as an adjunct to cognitive-behavioral psychotherapy. Int J Clin Exp Hypn. 2000 Apr;48(2):154–169.
17. Wade D. Rehabilitation for hysterical conversion states. A critical review and conceptual reconstruction. In: Halligan PW, Bass CM, Marshall JC, editors. Contemp Approaches Study Hysteria. Oxford ; New York: Oxford University Press; 2001.
Sedative medications in general quite often reduce symptoms from FND (e.g. benzodiazepines, baclofen, opiates), but the downside of these drugs are often very significant. This is particularly the case for pain, a very common accompaniment to FND. Many FND patients are on huge quantities of sedative medications like oral morphine, tramadol, codeine. These drugs do usually dull the pain to some extent, but they rarely reduce it significantly and in the long term the doses of the drugs have to escalate to get the same effect. This in turn leads to more side effects. In people where pain is a major component of symptoms it is often most helpful to direct people toward good quality holistic pain management clinics where medications are used alongside pain specific physiotherapy and cognitive therapy.
You must be logged in to post a comment.